QU100

QU100 is a novel Class I natural drug candidate developed by the Collaborative Innovation Center of Biotherapy (State Key Laboratory of Biotherapy) at Sichuan University. It is currently in development for the treatment of pulmonary fibrosis. The drug is formulated as a lyophilized powder for injection. As a Class I therapeutic in the Chinese regulatory framework, QU100 represents a new chemical or biological entity derived from natural sources that has not been previously marketed. While its specific molecular mechanism of action and biological targets have not been publicly disclosed in available pipeline documentation, it is being investigated for its potential to address fibrotic lung disease.